This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cognitest(TM) - Diagnostic Blood Test For Alzheimer's Disease - Milestone Attained

VANCOUVER, British Columbia, Feb. 28, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer's disease.

  • Simple, easy to use diagnostic blood test for Alzheimer's ready for clinical testing.
  • Human sample testing starting and to run over the next few months
  • Once validated, biOasis will apply for a CE mark in Europe for commercialization

Working in collaboration with Fleet Bioprocessing and OxFabs (Oxford, UK), the Company generated numerous antibodies and assessed their performance in prototype assays. The best performing mAbs were selected for use within production prototypes. The completion of this project enables the Company to initiate the validation of Cognitest™ with the use of clinical samples.

During the coming months biOasis plans to secure a number of blood samples from several sources for the purpose of assessing the technical performance of Cognitest™.

"The selection of monoclonal antibodies is an important step in the Cognitest™ program," says Rob Hutchison, biOasis Chairman and CEO. "Our strategy is to create new intellectual property and ensure ownership of key components within our products. We are now working to assess Cognitest™ using human samples from North America and Europe. Our intention is to expand the validation studies by collaborating with clinical thought leaders interested in an easy-to-use quantitative test for Alzheimer's disease. The ability to diagnose Alzheimer's has always been known to be very difficult due to the fact that many forms of dementia mimic Alzheimer's and as such a simple quick blood test would provide physicians with a tool to combat this dreadful disease." Please see:


biOasis is developing a proprietary diagnostic test for the diagnosis of Alzheimer's disease – Cognitest™. Current initiatives within the Cognitest program include product and method development, validation using human samples, and regulatory approval in Europe. To enable faster adoption and greater use of Cognitest the Company intends to out-license it to leading in vitro diagnostic companies. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs